Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 263

1.

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.

Lee S, Rauch J, Kolch W.

Int J Mol Sci. 2020 Feb 7;21(3). pii: E1102. doi: 10.3390/ijms21031102. Review.

2.

Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D.

Kennedy SA, Jarboui MA, Srihari S, Raso C, Bryan K, Dernayka L, Charitou T, Bernal-Llinares M, Herrera-Montavez C, Krstic A, Matallanas D, Kotlyar M, Jurisica I, Curak J, Wong V, Stagljar I, LeBihan T, Imrie L, Pillai P, Lynn MA, Fasterius E, Al-Khalili Szigyarto C, Breen J, Kiel C, Serrano L, Rauch N, Rukhlenko O, Kholodenko BN, Iglesias-Martinez LF, Ryan CJ, Pilkington R, Cammareri P, Sansom O, Shave S, Auer M, Horn N, Klose F, Ueffing M, Boldt K, Lynn DJ, Kolch W.

Nat Commun. 2020 Jan 24;11(1):499. doi: 10.1038/s41467-019-14224-9.

3.

RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy.

García-Gutiérrez L, McKenna S, Kolch W, Matallanas D.

Cancers (Basel). 2020 Jan 17;12(1). pii: E229. doi: 10.3390/cancers12010229. Review.

4.

All over the place: deciphering HRAS signaling from different subcellular compartments.

Kolch W, Matallanas D.

Mol Cell Oncol. 2019 May 20;6(5):e1605821. doi: 10.1080/23723556.2019.1605821. eCollection 2019.

PMID:
31528689
5.

An integrative computational approach for a prioritization of key transcription regulators associated with nanomaterial-induced toxicity.

Zhernovkov V, Santra T, Cassidy H, Rukhlenko O, Matallanas D, Krstic A, Kolch W, Lobaskin V, Kholodenko BN.

Toxicol Sci. 2019 Jul 4. pii: kfz151. doi: 10.1093/toxsci/kfz151. [Epub ahead of print]

PMID:
31271423
6.

Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.

Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.

Br J Cancer. 2019 Jul;121(1):37-50. doi: 10.1038/s41416-019-0477-7. Epub 2019 May 28.

7.

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wölfler A, Sill H, Zebisch A.

Haematologica. 2020 Jan 31;105(2):375-386. doi: 10.3324/haematol.2018.209650. Print 2020.

8.

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR.

Breast Cancer Res. 2019 Mar 21;21(1):43. doi: 10.1186/s13058-019-1127-y.

9.

An Integrated Global Analysis of Compartmentalized HRAS Signaling.

Santra T, Herrero A, Rodriguez J, von Kriegsheim A, Iglesias-Martinez LF, Schwarzl T, Higgins D, Aye TT, Heck AJR, Calvo F, Agudo-Ibáñez L, Crespo P, Matallanas D, Kolch W.

Cell Rep. 2019 Mar 12;26(11):3100-3115.e7. doi: 10.1016/j.celrep.2019.02.038.

10.

Systems biology: old news or new stimulus for biochemistry.

Kolch W, Fey D, Ryan CJ.

Essays Biochem. 2018 Oct 26;62(4):483-486. doi: 10.1042/EBC20180002. Print 2018 Oct 26.

PMID:
30366987
11.

From oncogenic mutation to dynamic code.

Kolch W, Kiel C.

Science. 2018 Aug 31;361(6405):844-845. doi: 10.1126/science.aau8059. No abstract available.

PMID:
30166473
12.

ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.

Monypenny J, Milewicz H, Flores-Borja F, Weitsman G, Cheung A, Chowdhury R, Burgoyne T, Arulappu A, Lawler K, Barber PR, Vicencio JM, Keppler M, Wulaningsih W, Davidson SM, Fraternali F, Woodman N, Turmaine M, Gillett C, Franz D, Quezada SA, Futter CE, Von Kriegsheim A, Kolch W, Vojnovic B, Carlton JG, Ng T.

Cell Rep. 2018 Jul 17;24(3):630-641. doi: 10.1016/j.celrep.2018.06.066.

13.

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.

Rukhlenko OS, Khorsand F, Krstic A, Rozanc J, Alexopoulos LG, Rauch N, Erickson KE, Hlavacek WS, Posner RG, Gómez-Coca S, Rosta E, Fitzgibbon C, Matallanas D, Rauch J, Kolch W, Kholodenko BN.

Cell Syst. 2018 Aug 22;7(2):161-179.e14. doi: 10.1016/j.cels.2018.06.002. Epub 2018 Jul 11.

14.

Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.

Verlande A, Krafčíková M, Potěšil D, Trantírek L, Zdráhal Z, Elkalaf M, Trnka J, Souček K, Rauch N, Rauch J, Kolch W, Uldrijan S.

EMBO Rep. 2018 Feb;19(2):320-336. doi: 10.15252/embr.201744524. Epub 2017 Dec 20.

15.

Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors.

Herrero A, Reis-Cardoso M, Jiménez-Gómez I, Doherty C, Agudo-Ibañez L, Pinto A, Calvo F, Kolch W, Crespo P, Matallanas D.

Small GTPases. 2017 Nov 26:1-13. doi: 10.1080/21541248.2017.1406434. [Epub ahead of print]

PMID:
29172991
16.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

17.

A Brain-Derived Neurotrophic Factor Mimetic Is Sufficient to Restore Cone Photoreceptor Visual Function in an Inherited Blindness Model.

Daly C, Shine L, Heffernan T, Deeti S, Reynolds AL, O'Connor JJ, Dillon ET, Duffy DJ, Kolch W, Cagney G, Kennedy BN.

Sci Rep. 2017 Sep 12;7(1):11320. doi: 10.1038/s41598-017-11513-5.

18.

Personalized Computational Models as Biomarkers.

Kolch W, Fey D.

J Pers Med. 2017 Sep 1;7(3). pii: E9. doi: 10.3390/jpm7030009.

19.

Lapatinib potentiates cytotoxicity of  YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter.

Radic-Sarikas B, Halasz M, Huber KVM, Winter GE, Tsafou KP, Papamarkou T, Brunak S, Kolch W, Superti-Furga G.

Sci Rep. 2017 Jun 8;7(1):3091. doi: 10.1038/s41598-017-03129-6.

20.

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.

Santra T, Roche S, Conlon N, O'Donovan N, Crown J, O'Connor R, Kolch W.

PLoS One. 2017 May 8;12(5):e0177058. doi: 10.1371/journal.pone.0177058. eCollection 2017.

Supplemental Content

Loading ...
Support Center